Scholarlink

Purpose <p>Colorectal cancer (CRC) remains a significant health burden worldwide. Although some clinicopathological factors have been identified in stage I-III CRCs, there is a need to identify new prognostic factors. This study aimed to investigate the clinical utility of circulating tumor DNA (ctDNA) methylation analysis in predicting the prognosis of stage I-III CRCs.</p> Methods <p>Methylation analyses were performed on 273 preoperative plasma samples from CRC patients who underwent surgery at Juntendo University Hospital between 2011 and 2019. The methylation levels of three tumor suppressor genes (<i>CHFR</i>, <i>SOX11</i> and <i>CDO1</i>) were analyzed as relative methylation value (RMV).</p> Results <p>There were no significant differences in the methylation levels of each gene among different stages of CRC. However, multivariate analysis revealed that the methylation level of <i>SOX11</i> was an independent prognostic factor (Hazard ratio (HR) = 2.37 (1.20–4.67), <i>p</i> = 0.01). Subgroup analysis of stage III CRC also showed methylation levels of <i>SOX11</i> and <i>CDO1</i> were independent prognostic factors (HR = 2.66 (1.16–6.07), <i>p</i> = 0.02 and HR = 2.51 (1.06–5.94), <i>p</i> = 0.04, respectively). In cases with high <i>CHFR</i> and <i>CDO1</i>-RMV, the use of postoperative adjuvant chemotherapy (POAC) was related to significantly higher RFS (<i>p</i> = 0.006 and <i>p</i> = 0.001, respectively). However, no significant effect of POAC was seen in high <i>SOX11</i>-RMV cases (<i>p</i> = 0.24).</p> Conclusions <p>This study demonstrated the clinical utility of ctDNA methylation analysis for predicting prognosis in stage I-III CRCs. Furthermore, the ctDNA methylation status might be a biomarker for identifying the patients who can benefit from POAC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Methylation Level of Circulating Tumor DNA Predicts Prognosis for Stage I-III Colorectal Cancer

  • 期刊论文

  • 发表日期：

    2026年1月15日

查看全文
  • Takahiro Irie,
  • Kiichi Sugimoto,
  • Hirotaka Momose,
  • Yuki Tsuchiya,
  • Ryoichi Tsukamoto,
  • Kumpei Honjo,
  • Hisashi Ro,
  • Shun Ishiyama,
  • Makoto Takahashi,
  • Thomas Pisanic,
  • Akio Saiura,
  • Kazuhiro Sakamoto

摘要

Purpose

Colorectal cancer (CRC) remains a significant health burden worldwide. Although some clinicopathological factors have been identified in stage I-III CRCs, there is a need to identify new prognostic factors. This study aimed to investigate the clinical utility of circulating tumor DNA (ctDNA) methylation analysis in predicting the prognosis of stage I-III CRCs.

Methods

Methylation analyses were performed on 273 preoperative plasma samples from CRC patients who underwent surgery at Juntendo University Hospital between 2011 and 2019. The methylation levels of three tumor suppressor genes (CHFR, SOX11 and CDO1) were analyzed as relative methylation value (RMV).

Results

There were no significant differences in the methylation levels of each gene among different stages of CRC. However, multivariate analysis revealed that the methylation level of SOX11 was an independent prognostic factor (Hazard ratio (HR) = 2.37 (1.20–4.67), p = 0.01). Subgroup analysis of stage III CRC also showed methylation levels of SOX11 and CDO1 were independent prognostic factors (HR = 2.66 (1.16–6.07), p = 0.02 and HR = 2.51 (1.06–5.94), p = 0.04, respectively). In cases with high CHFR and CDO1-RMV, the use of postoperative adjuvant chemotherapy (POAC) was related to significantly higher RFS (p = 0.006 and p = 0.001, respectively). However, no significant effect of POAC was seen in high SOX11-RMV cases (p = 0.24).

Conclusions

This study demonstrated the clinical utility of ctDNA methylation analysis for predicting prognosis in stage I-III CRCs. Furthermore, the ctDNA methylation status might be a biomarker for identifying the patients who can benefit from POAC.